Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Tumors: early-phase trial registry
43 of 127 indexed Solid Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #93 of 28,707 conditions by registered trial count.
127 US clinical trials · 43 currently recruiting · #93 of 28,707 conditions by registered trial count
Solid Tumors: 127 US clinical trials tracked, 43 recruiting.
Solid Tumors is the subject of 127 registered US clinical trials on ClinicalTrials.gov, 43 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 117 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 8 of these trials.
Enrollment posture brief
Registry condition solid-tumors
OPEN 43 | RECR 34% | LATE 4 | EARLY 117 | RANK #93 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)
Solid Tumors lists 43 open slots (34% of 127 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Solid Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Solid Tumors is recruiting below its size-band peers.
43 of 127 indexed trials (33.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Solid Tumors trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 8 of 127 trials (6.3%). 77 distinct sponsors appear on at least one study for this condition label.
-
Typical Solid Tumors enrolment sits around 70 participants.
Median target enrolment is 70 among the 126 trials that report a genuine target (sentinel values excluded). 72 of those (57.1%) plan for fewer than 100 participants.
-
Solid Tumors research is mostly interventional.
122 interventional and 5 observational studies make up this index (96.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
127 total, page 2 of 3
The Effects of Ginseng on Cancer-Related Fatigue
M.D. Anderson Cancer Center
NCT01375114
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
ModernaTX
NCT03313778
A Study of ADRX-0706 in Select Advanced Solid Tumors
Adcentrx Therapeutics
NCT06036121
Dexamethasone for Symptom Burden in Advanced Cancer Patients
M.D. Anderson Cancer Center
NCT00489307
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
NCT03709680
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Genentech
NCT03448042
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
NCT02521844
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Hoffmann-La Roche
NCT02650401
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
NCT05059522
Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT03813615
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Gilead Sciences
NCT06082960
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
Boehringer Ingelheim
NCT05327946
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation
NCT06818812
Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors
Children's National Research Institute
NCT02789228
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT02498912
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT03832569
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Incyte Corporation
NCT06873789
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
NCT00940225
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
Bristol-Myers Squibb
NCT02598960
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
NCT01197170
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Amgen
NCT05325866
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma
NCT02632448
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Amgen
NCT00531284
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
David Rizzieri, MD
NCT00580034
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Astellas Pharma
NCT00889382
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
NCT03314935
Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
NanoCarrier Co.
NCT02240238
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Ambrx
NCT03255070
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
NCT00770536
Clinical Trial of ARQ 761 in Advanced Solid Tumors
University of Texas Southwestern Medical Center
NCT01502800
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors
Genzyme, a Sanofi Company
NCT00942799
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Seagen
NCT01461538
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Incuron
NCT01905228
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
NCT04672460
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
NCT02350673
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
NCT00918281
A Study of Tor Kinase Inhibitor in Advanced Tumors
AstraZeneca
NCT00731263
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
Millennium Pharmaceuticals
NCT01862328
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Amgen
NCT00413283
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
Infinity Pharmaceuticals
NCT00606814
Oral ONC201 in Treating Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
NCT02250781
Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors
Pfizer
NCT00424632
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Millennium Pharmaceuticals
NCT01844583
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
National Cancer Institute (NCI)
NCT01445509
Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors
BPGbio
NCT01251562
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
David Rizzieri, MD
NCT00578942
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
CanBas Co.
NCT00551512
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Nuvation Bio
NCT02279433
Phase I Study of TAS-106 in Combo With Carboplatin
M.D. Anderson Cancer Center
NCT00752011
Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
Daiichi Sankyo
NCT01049893
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 102 |
| Phase 2 | 15 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Solid Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Solid Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Solid Tumors page
127 registered trials, 43 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 43 Solid Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Solid Tumors trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Tumors condition card totals 127 registered trials; most-linked intervention Gemcitabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.